Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

This trial was designed to investigate the safety, response rates and survival outcomes of patients with advanced solid tumors by trans-artery/intra-tumor infusion of PD1/PDL1 antibody and/or CTLA4 antibody ipilimumab plus chemotherapeutic drug and to compare their differences.

Trial Details

NCT ID
NCT03755739
Phase
PHASE2 / PHASE3
Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy
Locations (sample)
  • Guanzhou, Guangdong, China|23.06828,113.37117

Key Eligibility Criteria

  • Cytohistological confirmation is required for diagnosis of cancer.
  • Signed informed consent before recruiting.
  • Age above 18 years with estimated survival over 3 months.
  • Child-Pugh class A or B/Child score \> 7; ECOG score \< 2

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →